Noninvasive Risk Stratification of Lung Adenocarcinoma using Quantitative Computed Tomography  by Raghunath, Sushravya et al.
1698 Journal of Thoracic Oncology ®  •  Volume 9, Number 11, November 2014
Introduction: Lung cancer remains the leading cause of cancer-
related deaths in the United States and worldwide. Adenocarcinoma is 
the most common type of lung cancer and encompasses lesions with 
widely variable clinical outcomes. In the absence of noninvasive risk 
stratification, individualized patient management remains challenging. 
Consequently a subgroup of pulmonary nodules of the lung adenocar-
cinoma spectrum is likely treated more aggressively than necessary.
Methods: Consecutive patients with surgically resected pulmonary 
nodules of the lung adenocarcinoma spectrum (lesion size ≤3 cm, 2006–
2009) and available presurgical high-resolution computed tomography 
(HRCT) imaging were identified at Mayo Clinic Rochester. All cases 
were classified using an unbiased Computer-Aided Nodule Assessment 
and Risk Yield (CANARY) approach based on the quantification of 
presurgical HRCT characteristics. CANARY-based classification was 
independently correlated to postsurgical progression-free survival.
Results: CANARY analysis of 264 consecutive patients identi-
fied three distinct subgroups. Independent comparisons of 5-year 
disease-free survival (DFS) between these subgroups demonstrated 
statistically significant differences in 5-year DFS, 100%, 72.7%, and 
51.4%, respectively (p = 0.0005).
Conclusions: Noninvasive CANARY-based risk stratification identi-
fies subgroups of patients with pulmonary nodules of the adenocar-
cinoma spectrum characterized by distinct clinical outcomes. This 
technique may ultimately improve the current expert opinion-based 
approach to the management of these lesions by facilitating individu-
alized patient management.
(J Thorac Oncol. 2014;9: 1698–1703)
With an estimated 224,210 new cases and 159,260 deaths in 2014,1 lung cancer remains the leading cause of 
cancer-related mortality in the United States. Although early 
diagnosis offers a chance of cure, the majority of patients 
are diagnosed with advanced stage disease associated with 
extremely poor outcomes. Based on the 20% relative reduc-
tion in lung cancer-specific mortality observed in the National 
Lung Screening Trial (NLST),2 the US Preventive Services 
Task Force has issued recommendations in favor of High-
Resolution Computed Tomography (HRCT)-based screen-
ing.3 Consequently, lung cancer screening programs are being 
implemented across the United States.4–7 However, in addition 
to the early detection of aggressive lung cancers, screening 
leads to the detection of a substantial proportion of “overdi-
agnosed” lung cancers, that is, cancers unlikely to impact the 
overall survival of patients regardless of management.3,8,9 This 
could represent a substantial problem as an estimated 10.6 
million individuals would be eligible for HRCT screening in 
the United States alone based on NLST criteria.
Lung adenocarcinoma is the most common type of lung 
cancer. It typically presents as persistent solitary or multifo-
cal, solid or subsolid nodules on HRCT. Histologically, adeno-
carcinomas consist of various combinations of lepidic growth 
(noninvasive tumor cell growth along intact alveolar septa) and 
tissue invasion, corresponding generally to areas of ground-
glass attenuation and solid density, respectively on HRCT.10–12
Although most lung adenocarcinomas are aggressive, 
some have a more indolent course, clinically asymptomatic 
incidentally or screen-detected represent the majority of 
potentially overdiagnosed lesions. Current treatment strate-
gies are predominantly based on the size and location of the 
lesions, without assessment of lesion-specific aggressiveness, 
which may result in overtreatment (treatment of an otherwise 
asymptomatic indolent lesion) leading to unnecessary mor-
bidity, mortality, and healthcare expenses.2,8,9,13,14 Specifically, 
adenocarcinomas in situ (AIS) and minimally invasive ade-
nocarcinomas (MIA) are characterized by excellent (almost 
100%) postsurgical 5-year survival, whereas invasive adeno-
carcinomas (IA) have worse prognosis.15,16 These differences 
in clinical outcome are reflected in the recently updated clas-
sification of lung adenocarcinomas, which is based on the 
semiquantitative histologic assessment of these lesions.16 
In addition to clinical-pathological disease staging (Tumor-
Node-Metastasis (TNM) staging), comprehensive histological 
assessment represents the most powerful outcome predictor 
for these patients.16,17 Assuming that we can infer the biologi-
cal behavior of these lesions from these posttreatment out-
comes, noninvasive assessment through HRCT classification 
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could ultimately assist in the selection of alternative treatment 
strategies. However, currently risk assessment and tumor 
behavior prediction is limited to surgically resected lesions. 
Comprehensive histopathological assessment is not pos-
sible with small bronchoscopic or computed tomography 
(CT)-guided biopsies and no other noninvasive or minimally 
invasive biomarkers help to guide preoperative treatment 
strategies. Robust and reproducible noninvasive pretreatment 
risk stratification strategies are therefore urgently needed.
Computer-Aided Nodule Assessment and Risk Yield 
(CANARY) is a novel software application developed at Mayo 
Clinic, which allows automated HRCT-based quantitative char-
acterization of pulmonary nodules.18 We previously reported 
the excellent correlation between HRCT-based CANARY 
signatures and semiquantitative histology analysis. Herein 
we report a new CANARY-based risk stratification approach 
for pulmonary nodules of the adenocarcinoma spectrum. This 
noninvasive approach is independent of histologic assessment 
and addresses inherent limitations of histology such as inter-
observer variability and intratumor heterogeneity.19
MATERIALS AND METHODS
Data
We retrospectively identified consecutive patients with 
surgically resected solitary lung adenocarcinomas and an 
available preoperative HRCT (within 3 months of surgery) 
between January 2006 and December 2007. In addition, we 
included all consecutive cases with clinically stage I solitary 
pulmonary nodules (≤3 cm) resected between January 2008 
and December 2009. Clinical data including DFS was col-
lected from the Mayo Clinic electronic medical records. The 
study was approved by the Mayo Clinic IRB.
Nodule Characterization and 
CANARY Development
The development of CANARY has been described in 
detail.18 Briefly, a thoracic chest radiologist (BJB) arbitrarily 
selected 774 regions of interest (ROIs, 9 × 9 voxels) span-
ning the spectrum of radiologic appearance of adenocarcino-
mas (form pure ground-glass to pure solid) in 37 randomly 
selected pulmonary nodules. The similarity of the radiologic 
features between ROIs was compared using a pair-wise simi-
larity metric and nine characteristic ROI clusters (i.e., groups 
of radiologically similar ROIs) and corresponding “ROI 
exemplars” were identified using Affinity Propagation (AP),20 
an unsupervised clustering algorithm. Unlike other cluster-
ing algorithms, AP does not require the number of clusters to 
be specified before analysis, that is, it identifies natural clus-
ters with their most representative data point within the data 
set. The nine ROI exemplars were color-coded as violet (V), 
indigo (I), blue (B), green (G), yellow (Y), orange (O), red 
(R), cyan (C), and pink (P) and represent the basic building 
blocks of nodules of the adenocarcinoma spectrum. Nodules 
are analyzed by sequential analysis of each voxel within the 
nodule of interest. Each voxel (with its surrounding 80 vox-
els in a 9 × 9 voxel ROI) is compared with the nine identified 
ROI exemplars, and the color code of the most similar ROI 
exemplar is assigned to the analyzed voxel. The adjacent voxel 
is then analyzed in a similar fashion until all voxels contained 
in the nodule of interest have been color-coded, yielding a spe-
cific parametric signature for the nodule. This methodology 
and the parametric signatures have previously been validated 
by consensus histology of resected nodules in the adenocarci-
noma spectrum.18
Nodule Categorization and Quantitative 
Unsupervised Stratification
Given the correlation of histologic analysis with survival 
characteristics in pulmonary adenocarcinoma, we hypoth-
esized that CANARY-based parametric signatures of these 
nodules would correlate with prognosis, independent of his-
tology. Specifically, we postulated that the distribution of the 
nine ROI exemplars within individual nodules would correlate 
with the risk of disease progression, independent of histology, 
or clinical input, similar in that way to the comprehensive his-
tological assessment17 described in the updated classification 
of adenocarcinomas.16 To that end, we applied the same clus-
tering algorithm (AP) to identify natural clusters within the 
cohort of CANARY analyzed nodules to determine the type 
and number of groups of radiologically similar nodules based 
on the CANARY parametric signatures that constitute those 
nodules. DFS was compared between the resulting groups.
Nodule exemplars 
AP was used to identify natural clusters (clusters with 
similar distribution of parametric signatures) among lung 
adenocarcinomas. The most representative nodule or “nodule 
exemplar” was identified within each cluster that served as the 
reference for the cluster.
Nodule categorization 
All included clinical stage I solitary pulmonary nodules 
were categorized into one of the identified clusters by com-
paring the mathematical similarity (details in supplementary 
methods, Supplemental Digital Content 1, http://links.lww.
com/JTO/A683) of each nodule with the naturally identified 
nodule exemplars.
Cluster analysis 
The quantitative efficacy of the stratification was 
assessed for statistical significance using analysis of similar-
ity (ANOSIM).21
Survival Analysis
Follow-up data were collected retrospectively and post-
operative follow-up was not standardized. As reflected by the 
divergence in the guideline recommendations by different pro-
fessional organizations follow-up visits and imaging modali-
ties varied based on provider preferences.22–27 The majority 
of patients had follow-up at Mayo Clinic. In general patients 
were seen more often (every 3–6 months) during the first 2 
years and every 6 months between 3 and 5 years. The median 
follow-up was 3.07 years (last update: December 2013). Chest 
CT was the most often used imaging modality for follow-up. 
As expected, the majority of recurrences were distant metas-
tasis rather than pulmonary recurrences/metastasis. Deaths 
due to clearly documented other causes, in the absence of any 
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evidence for recurrent disease, were censored at the time of 
death. There were a total of 27 such events in the study cohort.
Kaplan-Meier analysis (GraphPad Prism version 5.00 
for Microsoft Windows, GraphPad Software, San Diego, CA) 
was performed to compare the DFS of the identified groups. 
The curves were compared using log-rank statistical test. Cox 
proportional hazard fit (JMP 10.0.0, SAS) was performed 
to form the multivariate model accounting for age, gender, 
smoking (never versus current/former), histologic staging, 
and stratified clusters. All patients had R0 surgical resections 
(curative resection) and clinical progression was defined as 
pathologically confirmed disease recurrence, as assessed by 
consensus of three of the author investigators (F.M., T.P., and 
Z.S.D.). The patients were censored at the time of their last 
follow-up in the absence of disease recurrence. p values less 
than 0.05 were considered significant.
RESULTS
Patients
Three-hundred six patients with surgically resected 
lung adenocarcinomas, January 2006 to December 2009 at 
Mayo Clinic, Rochester, MN, were included in our study. This 
included 264 cases of clinically stage I solitary pulmonary 
nodules. Demographic information and pathological tumor 
stages of these cases are summarized in Table 1.
Quantitative Nodule Characterization 
and Visualization
CANARY-based characterization of representative 
resected adenocarcinomas is illustrated in Figure 1. The 
glyphs represent a quantitative summary of the respective dis-
tribution of the ROI exemplars within each nodule. The radius 
of each glyph is set proportional to the volume of the nodule
Quantitative Nodule Categorization
The AP clustering using 170 cases of lung adenocar-
cinoma including 128 clinical stage I pulmonary nodules 
(2006–2007) yielded three natural clusters from which the 
three nodule exemplars were identified, and were secondarily 
found to represent predominantly B-G-C (1), mixed (2), and 
predominantly V-I-R-O nodules (3). Figure 2 shows the CT 
sections, color-coded patterns, and glyphs for the three nodule 
exemplars. ANOSIM yielded R = 0.6930 with p value = 0.001. 
Internal validation was successfully performed using leave-
one-out (LOO) and k-fold (k = 10) cross validation (CV) 
techniques (details in supplementary methods, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A683).
Correlation with DFS
All 264 clinical stage I pulmonary nodules of the lung 
adenocarcinoma spectrum were categorized into the identified 
three clusters. This categorization was statistically significant 
(ANOSIM R = 0.59; p value = 0.001). DFS was extracted in 
a blinded fashion and analyzed for these three clusters using 
KaplanMeier statistics. This analysis yielded 100%, 72.7%, 
and 51.4%, 5-year DFS for the three groups respectively 
(log-rank test p = 0.0005). Figure 3 shows the DFS curves. 
Based on this analysis the three groups were labeled as good 
(G), intermediate (I), and poor (P) risk. The log-rank test and 
univariate MantelHaenszel Hazard ratios (HR) revealed sta-
tistically significant differences between groups G and I with 
p value = 0.0055 (HR: 3.47 [1.44 to 8.22]); groups G and P 
with p value = 0.0002 (HR: 5.338 [2.23 to 12.78]); and groups 
I and P with p value = 0.02 (HR: 2.02 [1.10 to 3.73]). Table 2 
summarizes the multivariate cox proportional model using 
likelihood ratio tests for the stratified groups adjusted for age, 
gender, smoking history, and histologic staging as covariates.
DISCUSSION
In the present study, we report the use of a novel HRCT-
based imaging biomarker for the noninvasive risk stratifica-
tion of lung adenocarcinoma. We have identified three clusters 
of adenocarcinomas that naturally segregate using AP based 
on HRCT characteristics. Each of these clusters correlates 
strongly with the postsurgical DFS. Unlike other stratifica-
tion approaches,28 we did not use an outcome-matched trained 
model but identified these clusters independently of clinical 
data. Furthermore, in contrast to methods that differentiate 
lung nodules based on their HRCT appearance using various 
combinations of multiple quantitative features29,30 we used 
a single, robust similarity metric for objective risk stratifi-
cation. The three identified groups corresponded to good 
(G), intermediate (I), and poor (P) postoperative DFS. This 
strategy potentially facilitates the noninvasive classification 
of nodules prospectively in new patients. Inferring biologi-
cal behavior based on these known posttreatment outcomes, 
HRCT-based CANARY classification could ultimately guide 
the individualized management of these lesions. For example, 
nodules noninvasively categorized as “Good,” representing 
indolent lesions, could benefit from less aggressive surgical 
approaches, noninvasive or minimally invasive therapy or 
watchful waiting whereas nodules that have characteristics 
corresponding to the more aggressive lesions (P group) would 
be managed with current standard of care, such as lobectomy, 
and perhaps additional adjuvant therapy. The introduction of 
lung cancer screening is expected to result in a substantial 
increase in screening-detected lung cancers. Early detection is 
TABLE 1.  Patient Demographics and Pathological Tumor 
Stage
Demographics n = 264
Age at diagnosis
  Years: median (range) 68 (35–91)
Gender n (%)
  Women 141 (53)
Smoking n (%)
  Never 45 (17)
Pathologic TNM stage, n (%)
  I 216 (82)
  II 22 (8)
  III 23 (9)
  IV 3 (1)
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projected to decrease lung cancer-specific mortality; however 
an estimated 20% of patients with screening-detected lung 
cancer, almost exclusively adenocarcinomas, will potentially 
be overdiagnosed.9 This phenomenon could result in increased 
morbidity, mortality, and health care costs. In comparison to 
strategies mitigating the impact of false-positive pulmonary 
nodules, preoperative noninvasive risk stratification of pulmo-
nary nodules of the lung adenocarcinoma spectrum has been 
less well studied. Effective biomarkers to discriminate aggres-
sive from indolent lesions are urgently needed.3,31 Current 
therapeutic management decisions for these nodules currently 
rely on low-level evidence and expert opinion.12 For example, 
the selection of patients for limited surgical resection in ongo-
ing clinical trials is largely restricted to lesion size, highlight-
ing the need for accurate and consistent interpretation tools.32 
Ideally, treatment strategies including standard lobectomy, 
limited local resection (wedge or segmentectomy), stereotac-
tic body radiation therapy, and watchful waiting33,34 should be 
individualized based on the aggressiveness of the lesion.
Thus far quantitative imaging efforts for lung nodules 
have generally focused on nodule detection strategies.35–38 
Several CT-based techniques have been explored to charac-
terize pulmonary nodules.39–42 The majority of these studies 
focus exclusively on solid nodules. They utilize the shape 
characteristics like spiculation, nodule eccentricity, volume, 
and largest diameter. Correlation of these strategies with his-
tology and survival has been inconsistent.42,43
In real-world clinical practice, the variable HRCT acqui-
sition techniques, methods of image reconstruction, and filter-
ing from different CT scanner equipment can have enormous 
effects on the visual appearance of images and the quantitative 
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variability and assure that quantitative results are valid, an 
assessment of algorithm performance across multiple differ-
ent types of input is required. Our preliminary assessment 
suggests CANARY represents a robust risk stratification tool 
that can be utilized on a variety of HRCT techniques for ret-
rospective or prospective evaluation of lung nodules in a real-
world setting. Specifically, our results are consistent across a 
wide variety of clinically utilized CT protocols performed on 
various types of equipment. The stability of CANARY charac-
terization and stratification of scans reconstructed with sharp 
and smooth filtering algorithms are shown in Supplemental 
Figure 1 (Supplemental Digital Content 2, http://links.lww.
com/JTO/A684). Additional work to assess the specific limi-
tations of CANARY parametric signature quantification with 
regard to the effects of slice thickness, reconstruction method-
ology and other factors such as noise or dose-related changes 
in image characteristics may be warranted.
Our current report represents, to our knowledge, the first 
attempt using population imaging data and quantified radio-
logic characteristics to identify distinct clusters of lesions 
characterized by similar biologic behavior.
We acknowledge that prognostication based on a single 
time point is uncertain44 and the estimate of prognosis for an 
individual patient may change over time. As such, the applica-













Effect Likelihood Ratio Tests
Variable Chi-Square p Value
Age 1.22 0.26
Gender: male vs. female 3.46 0.06
Smoking: Never vs. current/former 3.36 0.06
Pathologic stage (I/II/III/IV) 2.08 0.55
Stratified groups (G/I/P) 19.75 <0.0001*
*P < 0.05 is considered significant.
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the natural history of pulmonary nodules of the lung adenocar-
cinoma spectrum. Determination of the rate of transition from 
indolent to aggressive characteristics or confident quantifica-
tion of stability may enable timely appropriate management of 
lesions through noninvasive HRCT assessment. With additional 
validation, we expect that this method will facilitate individual-
ized follow-up and management of pulmonary nodules of the 
lung adenocarcinoma in a standardized, objective fashion.
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